Compare AstraZeneca plc (AZN) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Global X Lithium & Battery Tech ETF — how do they compare? AstraZeneca plc trades at $166.67 (market cap $253.13B), while Global X Lithium & Battery Tech ETF trades at $71.22. The key difference: AstraZeneca plc pays a 1.92% dividend while Global X Lithium & Battery Tech ETF pays none, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | LIT | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $91.62 |
52-Week Low | $137.44 | $39.73 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
LIT trades at $70.24, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure. The stock has doubled over the past year, driven by strong EV and semiconductor demand. Recent news highlights global EV sales growth, particularly in Europe and China, supporting the lithium and battery technology sector. A dividend of $0.32 is scheduled for July 2026.
Outlook remains positive due to structural demand for lithium in energy storage and EVs, though risks include Chinese export controls and U.S. regulatory uncertainty. Analyst sentiment is mixed, with some highlighting momentum catalysts while technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
